LRP6 and breast cancer: In vivo efficacy was demonstrated using a transgenic murine model bearing mammary tumors driven by the mouse mammary tumor virus (MMTV)-Wnt1 oncogene since bardoxolone methyl administration markedly impaired tumor progression, reduced expression of phosphorylated and total LRP6, phosphorylated and unphosphorylated DVL2, active β-catenin, and downstream Wnt-responsive and CSC-associated transcripts.